| Name | MC2590 |
| Description | MC2590 is a potent and selective histone deacetylase (HDAC) inhibitor that inhibits HDAC1-3, -6, -8, and -10 activities, induces cell cycle arrest, and promotes apoptosis. |
| In vitro | MC2625/MC2590 (Compound 5e), over 72 hours, inhibits colorectal cancer cells HCT116 (IC50=0.07 μM), lung adenocarcinoma cells A549 (IC50=0.32 μM), and chronic myeloid leukemia cells K562 (IC50=0.05 μM) [1].At concentrations of 1 and 5 μM over 24 and 48 hours, MC2625/MC2590 induces G2/M cell cycle arrest [1].
At concentrations of 1 and 5 μM over 24 and 48 hours, MC2625/MC2590 induces excessive acetylation activity of H3K9/14, increases acetylated-α-tubulin levels, and significantly upregulates p21 protein [1].At concentrations of 1 and 5 μM over 48 hours, MC2625/MC2590 increases mRNA expression of p21, BAX, and BAK, downregulates cell cycle proteins D1 and BCL-2, and modulates pro-apoptotic and anti-apoptotic microRNAs to induce apoptosis [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | HDAC | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | Valproic Acid | Curcumin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | DNA Damage & Repair Compound Library | Reprogramming Compound Library | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | HIF-1 Signaling Pathway Compound Library | Hematonosis Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
